2014
Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults CHEST Guideline and Expert Panel Report
Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB. Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults CHEST Guideline and Expert Panel Report. CHEST Journal 2014, 146: 449-475. PMID: 24937180, PMCID: PMC4137591, DOI: 10.1378/chest.14-0793.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionHigh-level evidenceConsensus statementPharmacologic therapyAvailable evidenceArterial hypertensionGrades of RecommendationCochrane Library databasesExpert Panel ReportClinician adviceOptimal pharmacotherapyAdult patientsCHEST GuidelineGuideline recommendationsHigh-level recommendationsClinical questionsLibrary databasesSystematic reviewClinical decisionPharmacotherapyTherapyHypertensionEnglish-language evidenceLevel evidenceFurther studies
2013
Diagnosis of Pulmonary Arterial Hypertension
Forfia PR, Trow TK. Diagnosis of Pulmonary Arterial Hypertension. Clinics In Chest Medicine 2013, 34: 665-681. PMID: 24267297, DOI: 10.1016/j.ccm.2013.09.001.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionArterial hypertensionPulmonary venous hypertensionPopulation of patientsEchocardiographic cluesNonpharmacologic managementPulmonary hypertensionRight shuntingVenous hypertensionCardiac catheterizationClinical suspicionRight heartNoninvasive testsPhysical examLeft heartHigh indexHypertensionAccurate diagnosisDiagnosisCareful assessmentCatheterizationHeartPatientsShuntingSuspicionStandard Nonspecific Therapies in the Management of Pulmonary Arterial Hypertension
Sauler M, Fares WH, Trow TK. Standard Nonspecific Therapies in the Management of Pulmonary Arterial Hypertension. Clinics In Chest Medicine 2013, 34: 799-810. PMID: 24267305, DOI: 10.1016/j.ccm.2013.08.013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-dose calcium channel blockersCommon cardiopulmonary diseasesPAH-specific therapyPulmonary arterial hypertensionTreatment of patientsCalcium channel blockersPAH therapyArterial hypertensionAdjunct therapyOxygen therapyMedical therapyNonspecific therapyCardiopulmonary diseasePathologic understandingChannel blockersSmall studyTherapyHypertension researchExpert opinionAnticoagulationHypertensionDiureticsPatientsBlockersDigoxin
2012
IL-13 receptor α2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension
Cho WK, Lee CM, Kang MJ, Huang Y, Giordano FJ, Lee PJ, Trow TK, Homer RJ, Sessa WC, Elias JA, Lee CG. IL-13 receptor α2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2012, 304: l112-l124. PMID: 23125252, PMCID: PMC3543640, DOI: 10.1152/ajplung.00101.2012.Peer-Reviewed Original ResearchConceptsPulmonary hypertensionIL-13Human pulmonary artery smooth muscle cellsDevelopment of PHPulmonary artery smooth muscle cellsRight ventricle systolic pressurePathogenesis of PHArtery smooth muscle cellsExpression of ARG2Pulmonary arterial hypertensionPulmonary vascular remodelingVentricle systolic pressurePotential therapeutic targetIL-13 treatmentSmooth muscle cellsNull mutant miceArterial hypertensionEffector cytokinesMedial thickeningSystolic pressureHemodynamic changesPulmonary arterySmall-interfering RNAVascular remodelingArginase-2Targeted approaches to the treatment of pulmonary hypertension
Fares WH, Trow TK. Targeted approaches to the treatment of pulmonary hypertension. Therapeutic Advances In Respiratory Disease 2012, 6: 147-159. PMID: 22438264, DOI: 10.1177/1753465812441849.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionArterial hypertensionHigh-dose calcium channel blockersChest Physicians criteriaMultiple therapeutic optionsDurability of responseCalcium channel blockersTransplant evaluationPulmonary hypertensionOral therapyClose followPhysician's criteriaTherapeutic optionsChannel blockersEarly initiationAmerican CollegeHigh riskPatientsIncurable diseaseHypertensionEarly useStatus benefitsTreatmentDiseaseProgression
2009
Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism
Trow TK, Taichman DB. Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism. Respiratory Medicine 2009, 103: 951-962. PMID: 19304472, DOI: 10.1016/j.rmed.2009.02.016.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionEndothelin receptor antagonistsArterial hypertensionET-1Development of PAHManagement of PAHPathogenesis of PAHEndothelin receptor blockadeLiver function abnormalitiesPlacebo-controlled trialNitric oxide-mediated pathwayClinical study resultsGood clinical resultsClinical treatment studiesUnited States FoodPeripheral edemaFunction abnormalitiesReceptor blockadeDual antagonismDual blockadeSafety profileET receptorsEndothelin-1Head studiesReceptor antagonist
2007
Combination Therapy in the Treatment of Pulmonary Arterial Hypertension: Can That Dog Hunt?
Cho W, Trow T. Combination Therapy in the Treatment of Pulmonary Arterial Hypertension: Can That Dog Hunt? Clinical Pulmonary Medicine 2007, 14: 242-243. DOI: 10.1097/cpm.0b013e3180cac712.Peer-Reviewed Original Research
2005
Surviving Pulmonary Hypertension: An Oral Alternative?
Castiller F, Trow T. Surviving Pulmonary Hypertension: An Oral Alternative? Clinical Pulmonary Medicine 2005, 12: 281-282. DOI: 10.1097/01.cpm.0000171504.71068.5a.Peer-Reviewed Original ResearchTreatment of pulmonary arterial hypertensionPrimary pulmonary hypertensionEndothelin receptor blockersPulmonary arterial hypertensionPulmonary hypertensionArterial hypertensionIntravenous alternativeOral alternativeReceptor blockersImproved survivalAdvanced hypertensionHypertensionBosentanSurvivalPatientsBlockersEndothelinTreating Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension: Is Endothelin 1 a Target?
Trow T. Treating Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension: Is Endothelin 1 a Target? Clinical Pulmonary Medicine 2005, 12: 196-197. DOI: 10.1097/01.cpm.0000163121.24487.48.Peer-Reviewed Original ResearchHuman immunodeficiency virus-associated pulmonary arterial hypertensionNew York Heart Association functional classPulmonary arterial hypertensionPulmonary hypertensionCardiopulmonary hemodynamicsQuality-of-life measuresArterial hypertensionEndothelin-1Treated patientsDrug interactionsSide effectsFunctional classBosentanWalking distanceHypertensionEndothelinPatientsHemodynamics